SYNLOGIC INC (SYBX)

Company Profile

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 72 full-time employees. The company went IPO on 2015-09-30. The firm is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The firm uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. The firm also has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The firm has also developed two drug candidates through a research collaboration with Ginkgo Bioworks, Inc: SYNB1353, designed to consume methionine for the potential treatment of homocystinuria (HCU), and SYNB2081, designed to lower uric acid for the potential treatment of gout.

Company Info

SYNLOGIC INC

301 Binney St Ste 402

Cambridge MASSACHUSETTS 02142

P: 16174019975.0

CEO: Aoife Brennan

Employees: 72

Website: https://www.synlogictx.com/